ResApp Health Limited (ASX: RAP) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

ResApp Health Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • ResApp Health Limited (ASX: RAP)
    Latest News

    a woman
    52-Week Highs

    Why the ResApp share price rocketed 17% higher to a 52-week high today

    The ResApp Health Ltd (ASX:RAP) share price has rocketed higher for a second time this week. Here's why...

    Read more »

    a woman
    Share Gainers

    Why Nufarm, Paradigm, ResApp, & Zip Co shares charged higher today

    The Nufarm Limited (ASX:NUF) share price and the Zip Co Ltd (ASX:Z1P) share price are two of four charging higher...

    Read more »

    a woman
    Share Gainers

    ResApp share price surges 11% higher on positive update

    The ResApp Health Ltd (ASX:RAP) share price has been on fire on Monday morning. Here's why...

    Read more »

    a woman
    Share Gainers

    Why the ResApp share price rocketed 30% higher today

    The ResApp Health Ltd (ASX:RAP) share price rocketed 30% higher today after the release of a positive update on its…

    Read more »

    a woman
    Share Market News

    Top brokers name 3 ASX shares to buy

    Wesfarmers Ltd (ASX:WES) shares are one of three that brokers have named as buys this week…

    Read more »

    a woman
    Share Gainers

    Why Appen, Bubs, EML Payments, & ResApp shares stormed higher today

    The Bubs Australia Ltd (ASX:BUB) share price and the ResApp Health Ltd (ASX:RAP) share price are two of four storming…

    Read more »

    a woman
    Share Gainers

    Why the ResApp Health share price rocketed 36% higher today

    The ResApp Health Ltd (ASX:RAP) share price has been a big mover on Tuesday. Here's why...

    Read more »

    a woman
    Share Market News

    2 egregious investing mistakes to avoid

    Here are two amateur share market mistakes made by inexperienced retail investors.

    Read more »

    a woman
    Share Fallers

    Why the Admedus share price is sinking again on more big losses

    Admedus Ltd (ASX:AHZ) has been a sorry tale for shareholders.

    Read more »

    a woman
    Share Market News

    Leading brokers name 3 ASX shares to buy today

    The ResMed Inc (ASX:RMD) share price is one of three that leading brokers have tipped to climb higher...

    Read more »

    a woman
    Share Gainers

    Why BWX, Kogan, OceanaGold, and ResApp shares are storming higher

    The BWX Ltd (ASX:BWX) share price and the Kogan.com Ltd (ASX:KGN) share price have started the year with a bang…

    Read more »

    a woman
    Share Market News

    Are Mesoblast shares ready to shoot higher?

    Mesoblast limited (ASX:MSB) reported another quarter of significant cash outflows.

    Read more »

    RAP ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Roger Aston Non-Executive ChairmanNon-Executive Director Jul 2015
    Dr Aston is a scientist and seasoned biotechnology entrepreneur. He has been closely involved in start-up companies and major pharmaceutical companies. Aspects of his experience include US Food and Drug Administration (FDA) and European Union (EU) product registration, clinical trials, global licensing agreements, fundraising through private placements, and a network of contacts within the pharmaceutical, banking and stock broking sectors. Dr Aston has also held Directorships/Chairmanships with Clinuvel Ltd, HalcyGen Ltd, and Ascent Pharma Ltd, was a member of the AusIndustry Biological Committee advising the Industry Research and Development Board.
    Dr Michael Stein Non-Executive Director Apr 2020
    Dr Stein is currently acting CEO of immuno-oncology company, Valo Therapeutics. Immediately prior to Valo, he was the founding CEO of OxStem Ltd, an award-winning biotechnology spinout from the University of Oxford. Dr Stein previously served as founding CEO for Doctor Care Anywhere, a UK-based telemedicine platform acquired by Synergix in 2015. In 2001, he cofounded the Map of Medicine with University College London and was founding CEO.
    Mr Brian Willoughby Leedman Executive Director Corporate Affairs May 2021
    Mr Leedman is a marketing and investor relations professional with over 15 years' experience in the biotechnology industry. Mr Leedman is the founder of ResApp Diagnostics Pty Ltd which was acquired by Narhex Life Sciences Ltd to form ResApp Health. Prior to ResApp, Mr Leedman co-founded Oncosil Medical Limited and Biolife Science (QLD) Limited (acquired by Imugene Limited).
    Mr Christopher Ntoumenopoulos Non-Executive Director Jan 2015
    Mr Ntoumenopoulos is the Managing Director of Twenty 1 Corporate. He has worked in financial markets for the past 15 years, focusing on Capital Raisings, Portfolio Management and Corporate Advisory. Mr Ntoumenopoulos has advised and funded numerous ASX companies from early stage venture capital, through to IPO.
    Dr Anthony (Tony) Keating Chief Executive OfficerManaging Director Jul 2015
    Dr Keating has over ten years' experience in commercialising technology. Dr Keating created the initial business strategy for ResApp and has led the commercialization of ResApp's technology to date. Previously, Dr Keating was Director, Commercial Engagement at UniQuest Pty Ltd, one of the global leaders in commercialisation of university technology. While at UniQuest, Dr Keating held roles as interim Chief Executive Officer and Non-Executive Director for a number of privately-held, venture-capital funded start-up companies.
    Ms Nicola (Nicki) Maxine Farley Company Secretary
    -
    Nicola (Nicki) Maxine Farley Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 90,509,172 10.53%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retail Client Drp> 46,498,352 5.41%
    J P Morgan Nominees Australia Pty Limited 22,398,291 2.61%
    Mr Frank Weng Thong Chew 18,453,000 2.15%
    HSBC Custody Nominees (Australia) Limited <GSCO Customers A/C> 17,974,966 2.09%
    BNP Paribas Noms Pty Ltd <DRP> 14,977,050 1.74%
    HSBC Custody Nominees (Australia) Limited GSCO ECA 12,567,531 1.46%
    Mr Yongsheng Peng & Mrs Yuezhen Xie 11,667,602 1.36%
    Mr Anthony James Keating 10,225,000 1.19%
    Citicorp Nominees Pty Limited 9,962,873 1.16%
    Equimetrixs Pty Ltd <The Newtonmore Superannuation fund A/C> 8,437,500 0.98%
    Narhex Life Sciences Developments Pty Ltd 7,997,005 0.93%
    CEM International (Asia) Pty Ltd 7,849,888 0.91%
    Norfolk Enchants Pty Ltd <Trojan Retirement Fund A/C> 7,510,228 0.87%
    Mr Trent Antony Goodrick 7,000,000 0.81%
    Queensland Forest Industries Pty Ltd 6,502,500 0.76%
    Mishtalem Pty Ltd 6,500,000 0.76%
    Super Dino Pty Ltd <Dino Super A/C> 5,430,779 0.63%
    HSBC Custody Nominees (Australia) Limited A/C 2 5,378,484 0.63%
    Paranji Super Fund Pty Ltd <Paranji Superfund A/C> 5,285,000 0.61%

    Profile

    since

    Note